Entering text into the input field will update the search result below

Intellia gets upgrade at Brookline amid 'unchanged' patent risk on CRISPR/Cas9 technology

Mar. 07, 2022 11:43 AM ETIntellia Therapeutics, Inc. (NTLA)By: Ravikash, SA News Editor5 Comments

Genetic engineering

Andy/iStock via Getty Images

Intellia Therapeutics (NTLA -3.1%) was upgraded by Brookline Capital Management to Buy from Hold with a $91 price target.

Brookline analyst Leah Cann said the patent risk is unchanged, but the valuation has become attractive.

In February, the

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.